| Oct 4 |
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
|
| Sep 3 |
Compass Therapeutics to Participate in Upcoming Investor Events
|
| Sep 2 |
Compass Therapeutics files $300M mixed securities shelf
|
| Aug 22 |
Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
|
| Aug 12 |
Compass Therapeutics GAAP EPS of -$0.10, revenue of $0.85M
|
| Aug 12 |
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
|
| Aug 7 |
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
|
| Aug 6 |
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
|
| Jul 12 |
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
|
| Jun 20 |
Compass Therapeutics: Pointing Right At Some Tough Cancers
|
